In an article published in Nature Medicine, Moffitt Cancer Center researchers, led by Hatem Soliman, share results from a phase II clinical study of the oncolytic virus talimogene laherparepvec combined with standard chemotherapy in patients with early stage triple-negative breast cancer.
Awareness of breast density appears to increase one’s perceived breast cancer risk for a short time after undergoing mammography in Northern Manhattan according to a study at Columbia University Mailman School of Public Health.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Results from the SWOG S1416 clinical trial showed that adding veliparib to chemotherapy can significantly extend progression-free survival times in patients with TNBC that has a “BRCA-like” phenotype.
FDA approved Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
When Kay Dickersin was diagnosed with breast cancer in 1986, the support group available to her in Baltimore focused largely on how to get the makeup and wig to look right.
In an interview with the Cancer History Project, Kay Dickersin, one of the early leaders of the grassroots breast cancer patient advocacy movement, recounted the beginnings of the National Breast Cancer Coalition.
A regimen including oral paclitaxel plus Athenex (encequidar) in combination with a PD-1 inhibitor and carboplatin showed positive results in triple-negative, high-risk, early-stage breast cancer. The oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
An Indiana University School of Medicine study produced a potential biomarker for chemotherapy-induced cardiotoxicity in breast cancer patients. The researchers also identified a drug that may work to minimize cardiotoxicity.
